Vistagen's posters from the recent Anxiety and Depression Association of America (ADAA) Conference are now available! Explore new insights into social anxiety disorder (SAD) and fasedienol clinical trials on our Publications page: https://lnkd.in/enSDk7cc #ADAA2025
Vistagen
Pharmaceutical Manufacturing
South San Francisco, California 4,412 followers
Changing the trajectory of mental health care – One Mind at a Time
About us
Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage company leveraging its pioneering neuroscience and deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of intranasal product candidates called pherines. Each pherine product candidate in Vistagen’s neuroscience pipeline is designed to rapidly activate olfactory system and brain neurocircuitry to achieve desired therapeutic benefits and differentiated safety without requiring systemic absorption or binding to neurons in the brain. Vistagen’s neuroscience pipeline also includes an oral prodrug, AV-101, with potential to impact certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent disorders, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) associated with menopause. Connect at www.vistagen.com.
- Website
-
http://vistagen.com
External link for Vistagen
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 1998
Locations
-
Primary
Get directions
343 Allerton Ave
South San Francisco, California 94080, US
Employees at Vistagen
Updates
-
Our Vistagen team was proud to present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas last week! Ross Baker, PhD, MBA, our VP of Medical Strategy, was joined by our CEO Shawn Singh, JD, Aubrey Reider, our Senior Clinical Research Site Manager, and others on our clinical research team to share poster presentations exploring the age of onset of social anxiety disorder (SAD) in participants from fasedienol clinical trials, and new data on the characteristics of young adults with and without SAD. We are grateful for the opportunity to contribute to important conversations in mental health. #ADAA2025 #MentalHealthResearch #SocialAnxiety #Fasedienol
-
-
Life is stressful. The world is stressful. And let’s be honest— LinkedIn can be stressful sometimes too... In honor of Stress Awareness Month, we encourage you to pause your scrolling and take a deep breath. Your well-being matters, and small moments of rest can make all the difference. #StressAwarenessMonth #ScrollBreak
-
-
The Anxiety and Depression Association of America (ADAA) has created a powerful video highlighting the symptoms and experiences of those living with social anxiety disorder. Raising awareness is key to breaking stigma and ensuring more people get the support they need. Watch the video and join us in raising awareness of this disorder. Together, we can shine a light on the realities of social anxiety. #MentalHealthAwareness #SocialAnxiety #SocialAnxietyDisorder #ADAA
What is social anxiety disorder? Social anxiety disorder can make it hard to do everyday tasks like talking on the phone, ordering food, or interacting with friends or coworkers. Our latest video created in collaboration with Vistagen shares more about what social anxiety disorder is and how you can find support. Learn more: https://lnkd.in/eKnAMhP4 #Anxiety #SocialAnxiety #SocialAnxietyDisorder #AnxietySupport #AnxietyAwareness #MentalHealth #MentalHealthMatters #MentalHealthSupport
-
Vistagen will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada from April 3-5th. Poster presentations will explore the age of onset of social anxiety disorder (SAD) from fasedienol clinical trial participants, and new data on young adults with and without SAD. For details: https://bit.ly/3E3QBEy #ADAA2025
-
-
Today at 12:00pm ET, Shawn Singh will participate in a fireside chat during @Stifel’s 2025 Virtual CNS Forum. Watch the live webcast here: https://bit.ly/43IzAKC
-
-
🔬 On #CelebrateScientistsDay, we proudly recognize our very own Louis Monti, M.D., Ph.D. Dr. Monti is the pioneering mind behind pherines, our groundbreaking new class of intranasal product candidates harnessing the power and therapeutic potential of nose-to-brain neurocircuitry. Dr. Monti’s work is at the forefront of our mission to develop innovative, fast-acting solutions for multiple unmet medical needs. His commitment to neuroscience is helping to redefine what’s possible in mental health care, women’s health, and more. Join us in celebrating Dr. Monti and all the scientists at Vistagen and across the biopharmaceutical industry working to shape a brighter future! 👏 #CelebrateScientistsDay #MentalHealthInnovation #Pherines #ScienceForGood
-
-
Vistagen's CEO, Shawn Singh, will participate in a fireside chat during Stifel’s 2025 Virtual CNS Forum on Tuesday, March 18 at 12:00pm ET. For details, visit: https://bit.ly/4i6cthE
-
-
Today's neuroscience breakthroughs are redefining mental health treatment, with our novel nose-to-brain neurocircuitry approach leading the charge. Our CEO, Shawn Singh, JD, joined Brandon Li on the Power to the Patients podcast to discuss our pioneering approach and the potential of pherines. Listen here: https://apple.co/4bladk2
-
Vistagen’s President and Chief Executive Officer, Shawn Singh, will present a corporate overview at the 45th Annual TD Cowen Healthcare Conference on Monday, March 3, 2025, at 2:30 p.m. ET. For more details: https://bit.ly/4i99rc3
-